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treatment with latanoprost (p < 0.001); and the existence of oph-
thalmologic comorbidities, also with a 3-times higher hazard of
treatment withdrawal in patients that suffer an additional oph-
thalmic pathology (p < 0.007). The main reasons for treatment
drop-out were lack of efﬁcacy and the existence of intolerance
and/or adverse events, numerically superiors in the bimatoprost
and travoprost group. CONCLUSION: Latanoprost shows a
higher persistence degree vs. travoprost and bimatoprost in
routine clinical practice.
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OBJECTIVES: This controlled cross-sectional observational
study was conducted in 4 EU countries and Canada to assess the
burden of bilateral neovascular AMD on patient-reported func-
tioning and health resource utilization (HRU). METHODS: Of
the total 401 bilateral neovascular AMD patients and 471 elderly
non-AMD (control) subjects, 87 and 92 respectively were
French. After recording of Demographic and treatment data,
National Eye Institute Visual Function Questionnaire (NEI VFQ-
25), EuroQol (EQ-5D), Hospital Anxiety and Depression Scale
(HADS), history of falls, fractures and HRU were investigated
through a telephone survey. Comparisons needed chi-square
tests, analysis of variance, and multivariate regression models.
RESULTS: Mean age of AMD patients was 79 and 64% were
female. Comparisons were adjusted for age, gender, and comor-
bid diseases. The mean (95% CI) NEI VFQ overall scale scores
was 44.4 (36.2, 52.6) in AMD patients, vs 91.8 (86.2, 97.5) for
controls p < 0.0001. AMD patients also differed on the HADS
scales: anxiety score: 8.5 (6.3, 10.8) vs. 5.1 (3.5, 6.7),
p = 0.0005; depression scores: 7.1 (5.1, 9.1) vs. 2.9 (1.5, 4.4),
p < 0.0001. A negative trend is observed on EQ-5D: 0.6 (0.5,
0.7) vs. 0.7 (0.6, 0.8), p = 0.0893. In addition, 11.5% of AMD
patients fell in the past 12 months vs 3.3% of controls,
p = 0.053. Furthermore 41.4% of the AMD patients received
assistance for daily activities vs 6.5% of controls, p < 0.0001.
CONCLUSION: Bilateral AMD patients in France reported sub-
stantially worse QOL, poorer vision-related functioning, and
more anxiety and depression symptoms compared with a control
group.
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OBJECTIVES: To adapt the Glaucoma Symptom Scale (GSS) to
Iberian Spanish, and to study the psychometric properties of the
new version. The GSS scale is composed by 10 items, measuring
impact of glaucoma symptoms. Items should be answered for
both eyes. METHODS: An expert panel composed of two oph-
thalmologists, one gerontologist, two methodologists and one
pharma-economist supervised the adaptation procedure. Two
samples were recruited, one composed by 16 patients used to
check comprehension of the ﬁrst version, and 100 sample used
to obtain psychometric estimates. Patients were recruited in
Madrid, Zaragoza and Barcelona. Psychometric properties were
assessed for each eye and for between eyes average scores. Item
analysis, exploratory factor analysis and reliability estimates
were obtained. RESULTS: Patients ranged from 57 to 89 years
old and 50% were female. Symptoms were selected by 30% to
51% of patients, with a slight lower (p = 0.09) presence of symp-
toms in the right eye (mean = 4.3, SD = 3) than in the left eye
(mean = 4.6, SD = 3.1). A high correlation in the number of
symptoms present in each eye was found (r = 0.84, p < 0.001).
The scale could match the original proposed structure of a
functional domain and a non visual ocular symptom domain,
explaining 53% of available variance, but two items “tearing”
and “halos around lights” don’t exhibit high loadings. A three
dimensional structure would exhibit a better ﬁt. Dimensions
show mild correlations (0.14–0.36). Internal consistency is good
(Cronbach alpha = 0.82) and correlation between odd and even
items is moderate 0.653. Content validity was ensured by the
original researchers work. CONCLUSION: The Spanish version
of the GSS questionnaire shows acceptable psychometric prop-
erties. The two dimensional solution is supported although it
does not explain properly all symptoms. Further validity evi-
dences should be collected with special concern on screening
properties and responsiveness should be also evaluated.
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OBJECTIVES: The SF-36, a generic health-related quality of life
measure, comprises 8 domains (Ware 2000) for which physical
and mental component summaries (PCS and MCS) can be
derived (Ware, Kosinski 2001). Until now, no MID for the SF-36
domains and summary scores have been reported for patients
with active Crohn’s disease (CD). Our aims were to determine
the MID for SF-36 using data from the PRECiSE 1 trial (Sand-
born et al. 2006), and to use these MIDs for the interpretation of
results from the PRECiSE 2 trial investigating certolizumab pegol
maintenance treatment (Schreiber et al. 2005). METHODS:
SF-36 MIDs were estimated by anchor-based methods using
known meaningful changes in reference measures (Inﬂammatory
Bowel Disease Questionnaire [IBDQ] and CD Activity Index
[CDAI]). The a priori approach was to select the SF-36 MID
according to the most correlated anchor. Agreement of the
anchor-derived MIDs with results obtained using Standardised
Effect Sizes, Standard Errors of Measurement and Standard
Errors of the Difference was also evaluated. RESULTS: The two
anchors gave similar values of meaningful changes. The IBDQ,
which correlated most closely to SF-36 score changes, was
selected to derive the SF-36 MIDs. Results obtained with other
methods were in agreement with these derived MIDs and were
representative of small to moderate changes (effect sizes ranging
from 0.2 to 0.5). Based on these calculations, it was shown that
a signiﬁcantly higher proportion of patients showed a clinically
meaningful response in the SF-36 PCS and MCS after certoli-
zumab pegol maintenance treatment compared to patients
receiving placebo. CONCLUSION: A multi-faceted approach to
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determining MIDs for the SF-36 domain and summary scores
was investigated for the ﬁrst time in patients with active CD. This
enables a more meaningful interpretation of SF-36 scores in CD
patients.
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OF GASTROESOPHAGEAL REFLUX DISEASE (GORD)
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OBJECTIVES: To compare the efﬁcacy of esomeprazole with
that of the European licensed standard doses of PPIs for the relief
of GORD-associated symptoms in patients with reﬂux oesoph-
agitis (i.e. esomeprazole 40 mg once-daily compared with lanso-
prazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg, or
rabeprazole 20 mg once-daily). METHODS: A systematic review
of CENTRAL, BIOSIS, EMBASE and MEDLINE for randomised
controlled trials (RCTs) in patients with erosive oesophagitis was
conducted in January 2007. Data on relief of GORD symptoms
at 4 weeks were extracted and re-analysed if not analysed by
intention-to-treat. The summary effect estimate (relative risk
[RR]) was calculated by meta-analysis using a ﬁxed-effects
model. Publication bias was assessed using funnel plots.
RESULTS: Of 347 papers identiﬁed in the literature search, 11
were found to be head-to-head comparisons of a standard dose
of PPI and esomeprazole 40 mg. Five RCTs were excluded as
they did not contain any extractable data on the required out-
comes at 4 weeks. The remaining 6 RCTs were all randomised,
double-blind, double-dummy, had appropriate patient follow-up,
and were of sufﬁcient quality to be included. A meta-analysis
of complete resolution of heartburn showed that signiﬁcantly
more patients were heartburn-free with esomeprazole versus
other standard-dose PPIs (RR 1.08; 95% CI: 1.06 to 1.11;
p < 0.00001). Heartburn resolution was consistent across all
degrees of initial severity (mild, moderate, severe). There were no
signiﬁcant differences in treatment effect for dysphagia and epi-
gastric pain, but signiﬁcantly fewer patients had acid regurgita-
tion with esomeprazole versus other standard-dose PPIs (RR
1.03; 95% CI: 1.01 to 1.05; p = 0.002). Publication bias did not
appear to affect the results signiﬁcantly. CONCLUSION: Esome-
prazole signiﬁcantly improves symptoms of heartburn and acid
regurgitation when compared with other standard-dose PPIs in
patients with reﬂux oesophagitis.
GI DISORDERS—Cost Studies
PGI3
BUDGET IMPACT OF A UNIVERSAL ROTAVIRUS
VACCINATION PROGRAMME WITH ROTATEQ® IN FRANCE
Trichard M, Largeron N, Soum S, Saint-Sardos C
sanoﬁ pasteur MSD, Lyon, France
OBJECTIVES: The objective of the study was to assess the
budget impact of a universal rotavirus vaccination programme
with RotaTeq® in France from the French social security (SS)
and societal perspectives. METHODS: A decision analytic model
was developed following a birth cohort up to age 5. Epidemio-
logical parameters were taken from the French REVEAL study (a
prospective epidemiological study conducted in 2004–2005) and
from the literature. Costs were assessed by combining health care
resource utilization collected in the REVEAL study and unit
costs from ofﬁcial sources. Intention-to-treat effectiveness of the
vaccine was taken from a large worldwide clinical trial (REST
study, 70,000 children). The model estimates RVGE, vaccination
costs and net costs of a rotavirus vaccination programme with
RotaTeq® (90% coverage rate and current vaccine price) from
the French SS and societal perspectives. RESULTS: From the
French SS perspective, the introduction of RotaTeq® would
reduce the RVGE costs by 74% for a birth cohort followed up to
age 5, from €62.9 million to €16.2 million. The vaccination costs
would be €71.5 million. As 92% of RVGE costs occur during the
ﬁrst 24 months of life, 60% of the vaccination costs would be
recovered through prevented health care costs 2 years after the
implementation of the rotavirus vaccination programme. From
the societal perspective, the introduction of RotaTeq® would
reduce the RVGE costs by 75%, from €117.2 million to €29.6
million. The vaccination costs would be €110.1 million. As
89% of RVGE costs occur during the ﬁrst 24 months of life, 70%
of the vaccination costs would be recovered 2 years after
the implementation of the rotavirus vaccination programme.
CONCLUSION: In France, 60% and 70% of the rotavirus vac-
cination programme costs with RotaTeq® would be recovered 2
years after its implementation by the French SS and society
respectively.
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OBJECTIVES: This study evaluated cost, percentage of success-
fully treated patients and cost per successfully treated patient
comparing two branded Proton Pump Inhibitors (PPIs) often
prescribed in the UK, lansoprazole (oro-dispersible tablets) and
esomeprazole (tablets), for the acute management of uninvesti-
gated dyspepsia. METHODS: A decision analytic model was
used to simulate expected costs and outcomes in patients with
uninvestigated dyspepsia indicated for treatment with a PPI. The
primary outcome measure was the percentage of patients cured
within eight weeks, derived from studies directly comparing the
efﬁcacy of the two agents in this patient population. The analysis
considered use of PPI drugs, general practitioner visits, subse-
quent specialist consultations and endoscopy. Costs were esti-
mated from the perspective of the UK National Health Service.
Stochastic methods were used to determine conﬁdence intervals.
RESULTS: The expected proportion of patients healed after 8
weeks was 88.9% (95% CI 87.7%–90.1%) with lansoprazole
and 92.4% (91.4–93.3%) with esomeprazole. The expected cost
of treatment per patient with lansoprazole was £94.05 (£85.17–
£104.58) compared with £118.94 (£110.28–£128.83) with
esomeprazole. The incremental cost-effectiveness of esome-
prazole compared to lansoprazole was £711.77 (£465.41–
£1344.52) per additional patient achieving healing at eight
weeks. Sensitivity analysis exploring cost-effectiveness over 12
weeks found a cost-effectiveness of £2213 (£1487–£4087) per
additional patient achieving healing. Esomeprazole was signiﬁ-
cantly more expensive than lansoprazole (26% more at 8 weeks;
37% more at 12 weeks; p < 0.05 in both comparisons) and
delivered a small but diminishing therapeutic advantage (3.9% at
8 weeks; 1.9% at 12 weeks). CONCLUSION: For patients pre-
senting with uncomplicated reﬂux symptoms, treatment with
esomeprazole was signiﬁcantly more expensive than lansoprazole
and its therapeutic advantage was small.
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